news & events
ysios news
16.07.19
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
26.06.19
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise
02.04.19
Aura Biosciences Completes $40 Million Series D Financing
26.10.18
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26.09.18
Minoryx Therapeutics raises €21.3M in Series B funding round
24.09.18
Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners
16.03.18
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
31.01.18
QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing
15.11.17
Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs
21.07.17
Kala Pharmaceuticals Announces Pricing of Initial Public Offering
